Control Cohort for Plantar Fibroma

Phase-Based Progress Estimates
Plantar FibromaTreatment Cohort - Other
18 - 100
All Sexes
What conditions do you have?

Study Summary

Modern footwear has been implicated as a contributor to foot pathology and changes in the biomechanics of gait. In addition to footwear, the investigators propose that the lack of terrain variation may directly contribute to the development of common foot pathologies, resulting from decreased intrinsic foot muscle function. This study will examine the current understanding of terrain variation on foot musculature strength and its possible correlation with structural and functional changes within the foot.

Eligible Conditions
  • Plantar Fibroma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 9 weeks

Up to 9 weeks
Revised Foot Function Index (FFI-R)
Visual Analog Scale (VAS)

Trial Safety

Trial Design

2 Treatment Groups

Treatment Cohort
1 of 2
Control Cohort
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Control Cohort · No Placebo Group · N/A

Control CohortExperimental Group · 2 Interventions: Treatment Cohort, Control Cohort · Intervention Types: Other, Other
Treatment CohortActiveComparator Group · 2 Interventions: Treatment Cohort, Control Cohort · Intervention Types: Other, Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 9 weeks

Who is running the clinical trial?

University of FloridaLead Sponsor
1,248 Previous Clinical Trials
698,615 Total Patients Enrolled
Antony Merendino, DPMPrincipal InvestigatorUniversity of Florida

Eligibility Criteria

Age 18 - 100 · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: